JPWO2021163562A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021163562A5 JPWO2021163562A5 JP2022549103A JP2022549103A JPWO2021163562A5 JP WO2021163562 A5 JPWO2021163562 A5 JP WO2021163562A5 JP 2022549103 A JP2022549103 A JP 2022549103A JP 2022549103 A JP2022549103 A JP 2022549103A JP WO2021163562 A5 JPWO2021163562 A5 JP WO2021163562A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cells
- cell
- composition
- dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 146
- 238000000034 method Methods 0.000 claims description 91
- 210000004027 cell Anatomy 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 47
- 210000004443 dendritic cell Anatomy 0.000 claims description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 108091008874 T cell receptors Proteins 0.000 claims description 27
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000012642 immune effector Substances 0.000 claims description 24
- 229940121354 immunomodulator Drugs 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 230000021615 conjugation Effects 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 2
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- -1 inhalation Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976654P | 2020-02-14 | 2020-02-14 | |
| US62/976,654 | 2020-02-14 | ||
| PCT/US2021/017958 WO2021163562A2 (en) | 2020-02-14 | 2021-02-12 | Compositions and methods comprising splicing-derived antigens for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513605A JP2023513605A (ja) | 2023-03-31 |
| JPWO2021163562A5 true JPWO2021163562A5 (https=) | 2024-02-16 |
| JP2023513605A5 JP2023513605A5 (https=) | 2024-02-16 |
Family
ID=77295208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549103A Pending JP2023513605A (ja) | 2020-02-14 | 2021-02-12 | がんを処置するためのスプライシング由来抗原を含む組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240182518A1 (https=) |
| EP (1) | EP4103738A4 (https=) |
| JP (1) | JP2023513605A (https=) |
| CN (1) | CN115485395A (https=) |
| WO (1) | WO2021163562A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4055182A4 (en) * | 2019-11-08 | 2024-07-03 | The Regents Of The University Of California | IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT |
| US20250352576A1 (en) * | 2022-04-01 | 2025-11-20 | The Regents Of The University Of California | Methods and compositions for treating gliomas |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
| EP4695284A1 (en) * | 2023-04-11 | 2026-02-18 | The Regents of University of California | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US20180305776A1 (en) * | 2017-04-20 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Myc-reporters, cells containing myc-reporters and methods of use thereof |
| EP4055182A4 (en) * | 2019-11-08 | 2024-07-03 | The Regents Of The University Of California | IDENTIFICATION OF SPLICE-DRIVEN ANTIGENS FOR CANCER TREATMENT |
-
2021
- 2021-02-12 JP JP2022549103A patent/JP2023513605A/ja active Pending
- 2021-02-12 US US17/760,479 patent/US20240182518A1/en active Pending
- 2021-02-12 CN CN202180028467.5A patent/CN115485395A/zh active Pending
- 2021-02-12 EP EP21754447.7A patent/EP4103738A4/en not_active Withdrawn
- 2021-02-12 WO PCT/US2021/017958 patent/WO2021163562A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220204933A1 (en) | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens | |
| Cafri et al. | mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer | |
| Schuler et al. | The use of dendritic cells in cancer immunotherapy | |
| JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 | |
| JP6230208B2 (ja) | 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激 | |
| JP2022513148A (ja) | Ｔ細胞の改変 | |
| AU2005302425A1 (en) | Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use | |
| JP2011504101A5 (https=) | ||
| Adams et al. | Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes | |
| KR20150046346A (ko) | 항원 특이적 헬퍼 t 세포 리셉터 유전자 | |
| AU2016243628A1 (en) | Compositions and methods of treating cancer | |
| JP6602377B2 (ja) | 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途 | |
| Arienti et al. | Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes | |
| CA3037882A1 (en) | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same | |
| AU2024200316A1 (en) | Materials and methods for increasing immune responses | |
| AU2016243626A1 (en) | Compositions and methods of treating multiple myeloma | |
| JPWO2021163562A5 (https=) | ||
| RU2790867C1 (ru) | Способ активации цитотоксических Т-лимфоцитов в популяции мононуклеарных клеток крови при помощи мембранных везикул, полученных из генетически модифицированных опухолевых клеток меланомы М14 со сверхэкспрессией интерлейкина 2 | |
| RU2846426C2 (ru) | Способ получения человеческого Т-клеточного рецептора, специфичного для эпитопа 369-377 рецептора HER2/neu (ERBB2) | |
| JPWO2022216856A5 (https=) | ||
| JPWO2022225852A5 (https=) | ||
| WO2026018922A1 (ja) | ＳＡＲＳ－ＣｏＶ－２感染症治療および／または予防用細胞及びその製法 | |
| JPWO2023004289A5 (https=) | ||
| CN114599378A (zh) | 用于肿瘤的治疗和/或预防的组合物 | |
| Immunother | International Society for Biological Therapy of Cancer |